Literature DB >> 586099

Comparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients: a randomized prospective trail.

W K Lau, L S Young, R E Black, D J Winston, S R Linne, R J Weinstein, W L Hewitt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 586099     DOI： 10.1016/0002-9343(77)90669-6

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  26 in total

Review 1.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 2.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

4.  Serum bactericidal activity of mezlocillin, ceftazidime, mezlocillin/ceftazidime and mezlocillin/amikacin against Klebsiella pneumoniae and Pseudomonas aeruginosa.

Authors:  Y Van Laethem; J Klastersky
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

5.  Tobramycin nephrotoxicity. A prospective clinical study.

Authors:  A Coca; J Blade; A Martinez; F Segura; E Soriano; M Ribas-Mundo
Journal:  Postgrad Med J       Date:  1979-11       Impact factor: 2.401

6.  Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.

Authors:  H C Standiford; G L Drusano; B Fitzpatrick; B Tatem; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-09       Impact factor: 5.191

7.  Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model.

Authors:  L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.

Authors:  J H Joshi; K A Newman; B W Brown; R S Finley; R L Ruxer; M A Moody; S C Schimpff
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

9.  [Clinical efficacy, nephrotoxicity and ototoxicity of amikacin].

Authors:  P Federspil; K Schindler; C Weich; E Tiesler; W Schätzle; M Ziegler
Journal:  Infection       Date:  1979       Impact factor: 3.553

10.  Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.

Authors:  J Klastersky; M P Glauser; S C Schimpff; S H Zinner; H Gaya
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.